Skip to main content

Vioxx News

FDA Medwatch Alert: Vioxx (rofecoxib) - Apr 7, 2005

After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: *...

FDA Medwatch Alert: Vioxx (rofecoxib) - Jun 15, 2005

FDA has requested that sponsors of all non-steroidal anti-inflammatory drugs (NSAID) make labeling changes to their products. FDA recommended proposed labeling for both the prescription and...

FDA Medwatch Alert: Vioxx (rofecoxib) - Sep 30, 2004

Merck & Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib) from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events (including heart attack...

FDA Medwatch Alert: Vioxx (rofecoxib) - May 6, 2002

FDA and Merck strengthened the WARNINGS, PRECAUTIONS, and CLINICAL STUDIES sections of Vioxx labeling to describe new cardiovascular and gastroenterological safety information. This information...

FDA Medwatch Alert: COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: *...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Migraine, Osteoarthritis, Pain, Period Pain, Dysmenorrhea, Rheumatoid Arthritis

Vioxx patient information at Drugs.com